The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2019 | Glasdegib therapy for MDS and AML
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the use of glasdegib therapy for relapsed/refractory myelodysplastic syndromes and oligoblastic acute myeloid leukemia at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
